Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Data disclosure in Jordan


Published on

Presentation by Abeer Rabayah, MeTA Jordan Secretariat / Technical Officer during the MeTA countries sharing meeting, London 2009.

  • Be the first to comment

  • Be the first to like this

Data disclosure in Jordan

  1. 1. Pharmacist :Abeer Rabayah MeTA Jordan Secretariat/ Technical Officer Data Disclosure in Jordan MeTA 18/01/10
  2. 2. Type of data being collected <ul><li>Data in the four core areas that covers: </li></ul><ul><li>Polices/ laws and regulations </li></ul><ul><li>Practices and procedures </li></ul><ul><li>Availability status of each key disclosure data </li></ul><ul><li>Reasons behind unavailability of some data </li></ul><ul><li>Reasons behind not publishing /disclosing some of the available data </li></ul>18/01/10 MeTA
  3. 3. Overview of disclosure process and engagement of stakeholders  <ul><li>Data Disclosure Survey Tool was sent to all members by mail to have an overview. </li></ul><ul><li>Start discussing the tool and it’s rational with each committee especially within their areas of expertise and getting feedback on the best way to precede working. </li></ul><ul><li>Based on MeTA council members suggestion , the national MeTA Secretariat Organized three special MeTA Council Meetings to discuss the key disclosed data ( average spent time:2 hours per meeting). </li></ul><ul><li>Collected data was categorized in special tables in order to be verified and accurately referenced based on its official sources. </li></ul>18/01/10 MeTA
  4. 4. Challenges & lessons Learned <ul><li>Challenges </li></ul><ul><li>Most of key stakeholders who represent the official resources of Data have limited time. </li></ul><ul><li>Limited contribution from CSO members </li></ul><ul><li>Key disclosure Data regarding Medicines Availability to consumer is difficult to obtain ( WHO-HAI survey and Baseline pharmaceutical assessment survey is still ongoing) </li></ul><ul><li>Some key Data sources were not easily accessible (a fees is needed to obtain the data) </li></ul>18/01/10 MeTA
  5. 5. Challenges & lessons Learned <ul><li>Lessons Learned </li></ul><ul><li>Sharing Data among stakeholder is important to stimulate discussion and asking questions. </li></ul><ul><li>Data disclosure meeting raised some useful and important recommendations. </li></ul><ul><li>Stakeholders exchanged data among each other and learned new things that they didn't previously now. </li></ul><ul><li>Data disclosure meetings was an opportunity for different stakeholder to understand why some Data are not disclosed. </li></ul><ul><li>Data disclosure meetings uncovered some of the official website’s weaknesses that hinder accessibility to published data. </li></ul>18/01/10 MeTA
  6. 6. Type of support needed <ul><li>To conduct one workshop about the importance of Data Disclosure and its added value especially for the private sector as it consider most of its data confidential. </li></ul><ul><li>To support us in transforming Data disclosure to become a systemised process. </li></ul><ul><li>To exchange ideas and disclosure process with other countries where Data disclosure is more developed. </li></ul>18/01/10 MeTA
  7. 7. Data Disclosure Survey Tool 18/01/10 MeTA Lessons Learned Challenges
  8. 8. Thank you! <ul><li>Abeer Rabayah </li></ul><ul><li>[email_address] </li></ul><ul><li>+962 7 99555194 </li></ul><ul><li> </li></ul>18/01/10 MeTA